Project Grant R01CA303150
Award Date 9/10/25
Completion Date 8/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Michigan, USA
Similar Awards
- This $627,422 Project Grant award from the National Cancer Institute under the Cancer Treatment Research (CFDA 93.395) program supports research by the Regents of the University of Michigan to engineer commensal bacteria that can neutralize the colibactin genotoxin produced by certain gut bacteria associated with increased colorectal cancer risk. The key products and services to be delivered under this 5-year grant include: 1) Further optimization of the surface display of the anti-toxin...
- This $1,355,273 Project Grant was awarded by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) to the Regents of the University of Michigan. The grant funds the development of two complementary approaches to inhibit the production of the bacterial metabolite colibactin, which has been linked to colorectal cancer and microbiome dysbiosis. The first approach involves enzymatic inactivation of colibactin through...
- The National Cancer Institute (NCI) has awarded a $727,904 Cooperative Agreement to The Trustees of Columbia University in the City of New York, doing business as the Health Sciences Division, under the Cancer Biology Research program (CFDA 93.396). The purpose of this 23-month award, with a start date of August 11, 2025, is to engineer probiotic bacteria (E. coli Nissle 1917) to identify precancerous lesions, characterize novel stage-specific immune targets, and design immunomodulatory...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This $248,998 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research by The General Hospital Corporation (Massachusetts General Hospital) to identify gut microbial and metabolomic biomarkers that link the consumption of ultra-processed foods to colorectal cancer risk. The research will leverage multi-omics data from large prospective cohorts and integrate a medically tailored meal intervention into the oncology care of colorectal...
- This federal Project Grant award of $400,890.00 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient, microsatellite-stable colorectal tumors. The goal is to provide a strategic roadmap and personalized workflow to enhance immunotherapeutic effects on non-responsive...
- This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $221,456.00 to the Regents of the University of Minnesota to develop and optimize a novel approach for enriching microbes from clinical cancer samples. The goal is to enable deep metaproteomic analysis and characterize the functional proteins contributed by microbes that influence the tumor microenvironment during cancer development. The project will pursue two specific...
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $392,827 to Endure Biotherapeutics, Inc. to develop a novel engineered native bacteria (ENB) therapy for the treatment of familial adenomatous polyposis (FAP), a genetic condition that leads to colorectal cancer. The project aims to engineer gut bacteria to express therapeutic gene products that can effectively colonize the gut and suppress the progression of colon adenomas, thereby...
- The federal Project Grant award of $697,763 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The University of Texas MD Anderson Cancer Center to decipher the critical determinants of how the Fusobacterium nucleatum (FN) bacteria colonizes the colorectal cancer (CRC) tumor microenvironment and contributes to disease progression. The project aims to gain mechanistic insights into how this oral bacteria homes to and persists within the CRC tumor, as...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research at Stanford University to investigate how the human gut microbiome can be modulated to enhance immune responses against cancer, with a focus on improving the efficacy of cancer immunotherapy treatments. The $179,988 award, which runs from January 1, 2025 to December 31, 2026, aims to identify bacterial genes and functions that can boost the body's immune response to immune...